10-Q: Healthpeak Reports Q3 Loss Amid Lab Impairments

Healthpeak Properties, Inc. reported a net loss of $117.3 million for Q3 2025, primarily due to significant impairment charges in its lab joint ventures, despite revenue growth.

Summary

• Reported a net loss applicable to common shares of $117.3 million ($0.17 per diluted share) for the three months ended September 30, 2025, a significant decline from a net income of $85.7 million ($0.12 per diluted share) in the prior year period.
• For the nine months ended September 30, 2025, the company recorded a net loss of $43.3 million ($0.06 per diluted share), compared to a net income of $238.0 million ($0.36 per diluted share) in the same period of 2024.
• Nareit FFO increased to $318.2 million for Q3 2025 from $311.2 million in Q3 2024, and to $940.4 million for the nine months ended September 30, 2025, from $785.9 million in the prior year period.
• FFO as Adjusted rose slightly to $318.8 million in Q3 2025 from $316.2 million in Q3 2024, and to $965.1 million for the nine months ended September 30, 2025, from $907.1 million in the prior year period.
• AFFO decreased to $292.0 million in Q3 2025 from $296.0 million in Q3 2024, but increased to $904.0 million for the nine months ended September 30, 2025, from $833.3 million in the prior year period.
• Total revenues for Q3 2025 were $705.9 million, up from $700.4 million in Q3 2024. For the nine months, total revenues increased to $2.10 billion from $2.00 billion.
• Adjusted NOI for the total portfolio decreased by 1.0% in Q3 2025, but increased by 4.2% for the nine months ended September 30, 2025.
• The lab segment experienced a 3.2% decrease in Merger-Combined Same-Store Adjusted NOI and a drop in occupancy to 93.2% in Q3 2025 from 97.7% in Q3 2024.
• The CCRC segment showed strong performance with a 9.4% increase in Merger-Combined Same-Store Adjusted NOI and average occupancy rising to 86.7% in Q3 2025 from 85.2% in Q3 2024.
• Outpatient medical segment's Merger-Combined Same-Store Adjusted NOI increased by 2.0% in Q3 2025, with occupancy at 91.4%.

Sentiment

Score: 4

Explanation: The significant net loss and impairment charges in the lab segment, coupled with declining lab occupancy and increased interest expense, indicate a challenging period. While the CCRC segment shows strength and the company is actively managing its portfolio and debt, the magnitude of the lab-related setbacks weighs heavily on overall sentiment.

Positives

• CCRC segment demonstrated strong operational performance with a 9.4% increase in Merger-Combined Same-Store Adjusted NOI and a rise in average occupancy to 86.7% in Q3 2025.
• Outpatient medical segment showed positive growth with a 2.0% increase in Merger-Combined Same-Store Adjusted NOI for Q3 2025.
• Cash flows from operating activities increased by $171 million for the nine months ended September 30, 2025, driven by lower merger-related costs, increased NOI from acquired properties, and new leasing activity.
• Successfully issued $500 million of 5.38% senior unsecured notes due 2035 and $500 million of 4.75% senior unsecured notes due 2033, demonstrating continued access to capital markets.
• Repurchased 5.09 million shares of common stock for $94 million under the 2024 Share Repurchase Program, indicating management's confidence and commitment to shareholder returns.
• Received full repayment of $106 million in senior housing seller financing loans and a $15 million secured loan, improving liquidity.
• Completed the implementation of a new enterprise resource planning (ERP) system in Q2 2025, which could lead to operational efficiencies.

Negatives

• Incurred significant other-than-temporary impairment charges of $169 million on South San Francisco lab joint ventures and $7 million on the Needham Land Parcel JV in Q3 2025, leading to a net loss.
• Net income (loss) applicable to common shares decreased substantially, moving from a profit of $85.7 million in Q3 2024 to a loss of $117.3 million in Q3 2025.
• Diluted EPS turned negative at $(0.17) in Q3 2025, down from $0.12 in Q3 2024.
• The lab segment experienced a decline in occupancy (93.2% in Q3 2025 vs. 97.7% in Q3 2024) and a 3.2% decrease in Merger-Combined Same-Store Adjusted NOI for Q3 2025, reflecting challenges in the life science industry.
• Interest expense increased for both the three and nine months ended September 30, 2025, due to new debt issuances and higher commercial paper borrowings.
• Gain on sales of real estate decreased significantly in 2025 compared to 2024, indicating fewer large-scale dispositions.

Risks

• Macroeconomic trends, including higher interest rates and inflation, may increase construction, labor, and other operating costs.
• Changes within the life science industry, including depressed biotechnology capital raising, lower market rents, increased capitalization rates, and oversupply, are adversely affecting lab tenants and property values.
• Factors adversely affecting tenants, operators, or borrowers' ability to meet financial and contractual obligations, potentially leading to insolvencies or bankruptcies.
• Illiquidity of real estate investments could limit the ability to dispose of properties quickly or at desired prices.
• Property development, redevelopment, and tenant improvement risks can render projects less profitable or delay completion.
• Increased borrowing costs could impact the ability to refinance existing debt, sell properties, and conduct investment activities.
• Covenants in debt instruments may limit operational flexibility, and breaches could trigger adverse consequences.
• Volatility, disruption, or uncertainty in the financial markets could impact capital availability and cost.

Future Outlook

The company anticipates that its cash flows from operations, available cash balances, and various financing activities will be adequate for the next 12 months and the foreseeable future to fund recurring operating expenses, meet debt service requirements, and satisfy dividend distributions. Longer-term liquidity needs include funding capital expenditures, acquisitions, developments, and other investment commitments, which are expected to be met through cash flows, asset sales, borrowings, and equity issuances. The company is evaluating the impact of new FASB accounting standards updates on income tax and expense disaggregation disclosures, effective for annual periods beginning after December 15, 2024, and 2026, respectively.

Management Comments

• Our strategy is to own, operate, and develop high-quality real estate focused on healthcare discovery and delivery.
• We manage our real estate portfolio for the long-term to maximize risk-adjusted returns and support the growth of our dividends.
• We maintain a strong investment-grade balance sheet with ample liquidity as well as long-term fixed-rate debt financing with staggered maturities to reduce our exposure to interest rate volatility and refinancing risk.
• We provide high-quality property management services to encourage tenants to renew, expand, and relocate into our properties, which drives increased occupancy, rental rates, and property values.
• We continually strive to create and maintain an industry-leading platform, with systems and tools that allow us to effectively and efficiently manage our assets and investment activity.

Industry Context

The filing highlights that the company's operating results are impacted by global and national economic and market conditions, including higher interest rates and uncertainty in public and private equity and fixed income markets, leading to increased costs and limitations on capital availability. Specifically, the life science industry is facing challenges such as depressed biotechnology capital raising, lower market rents, increased capitalization rates, and oversupply, which contributed to the significant impairment charges. This indicates a challenging environment for the lab segment, contrasting with the more stable or growing outpatient medical and CCRC segments, which benefit from universal healthcare demand and increased resident fees/occupancy, respectively.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• No legal proceedings or claims are currently known that are believed to have a material adverse effect on the company's financial condition, results of operations, or cash flows.

Related Party Transactions

• The company has indemnification agreements on 28 properties within its DownREITs, obligating it to reimburse members for federal and state income taxes associated with pre-contribution gains if properties are sold in a taxable transaction within a specified number of years.
• The company owns a 49% interest in the Lab JV and is generally obligated to indemnify its joint venture partner for federal and state income taxes associated with gains existing at the time of contribution if the property is sold in a taxable transaction.

Stakeholder Impact

• Shareholders: Negative impact due to net loss and diluted EPS turning negative, primarily from impairment charges. Share repurchases offer some support.
• Employees: Merger-related synergies led to lower compensation expense, potentially indicating workforce adjustments. Stock-based compensation is a component of employee remuneration.
• Customers (tenants/residents): Lab tenants face industry headwinds (depressed capital raising, oversupply). CCRC residents benefit from increased occupancy and potentially stable services.
• Creditors: Debt levels increased, but the company maintains an investment-grade balance sheet and successfully refinanced/issued new notes. Fixed-rate debt dominates, reducing interest rate volatility exposure.

Next Steps

• Continue to fund the remaining $5 million commitment for the HQ Point Preferred Equity Investment in 2025.
• Fund the remaining $9 million commitment for Other Equity Investments over the next four years.
• Monitor the impact of new FASB accounting standards updates on income tax and expense disaggregation disclosures, effective for annual periods beginning after December 15, 2024, and 2026, respectively.
• The 2024 Share Repurchase Program, with $406 million remaining, expires in July 2026 and may be utilized at management's discretion.

Key Dates

Recommendation

The company's Q3 2025 results show a significant net loss driven by substantial impairment charges in its lab segment, reflecting ongoing challenges in the life science industry. While the CCRC segment is performing strongly with increased occupancy and NOI, and the outpatient medical segment shows modest growth, the weakness in the lab portfolio is a material concern. The company has demonstrated financial agility through debt refinancing and share repurchases, maintaining a strong balance sheet. However, the negative EPS and the specific industry headwinds for lab properties warrant caution. For existing investors, holding the stock to monitor the effectiveness of portfolio management and the recovery of the lab market, while benefiting from the stable CCRC and outpatient medical segments, seems appropriate. New investment would be speculative given the current uncertainties and impairment.

Keywords

Healthcare REIT, Real Estate Investment Trust, Outpatient Medical, Lab Properties, Life Science, CCRC, Continuing Care Retirement Community, SEC Filing, Financial Results, Property Acquisitions, Property Dispositions, Debt Issuance, Share Repurchase, Impairment Charges, Occupancy Rates, Adjusted NOI, FFO, AFFO